Supernus Pharmaceuticals (SUPN) Osake Kurssi

Supernus Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The main competitors of Supernus Pharmaceuticals Inc in the market are other pharmaceutical companies that specialize in the same therapeutic areas and products. Some of these competitors include companies like Johnson & Johnson, Pfizer Inc, Novartis AG, and Eli Lilly and Company. These companies also have a strong presence in the pharmaceutical industry and offer similar medications and treatments. However, Supernus Pharmaceuticals Inc differentiates itself through its unique product offerings and innovative research and development efforts.

Supernus Pharmaceuticals Inc is a pharmaceutical company specializing in the development and commercialization of innovative therapies for central nervous system diseases. Founded in 2005, Supernus has a strong history of success in bringing quality treatments to patients. Headquartered in Rockville, Maryland, the company has focused on researching and developing products for the treatment of epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological disorders. Supernus Pharmaceuticals Inc has established itself as a leading player in the pharmaceutical industry, delivering innovative solutions for patients and healthcare professionals. With a dedication to improving patient lives, Supernus continues to make significant contributions to the medical field through its advanced therapies.

Supernus Pharmaceuticals Inc has achieved several significant milestones throughout its history. Notable achievements include the FDA approval of their flagship product, Trokendi XR, for the treatment of epilepsy and migraines. The company has also successfully launched Oxtellar XR, an antiepileptic drug, in the United States market. In addition, Supernus Pharmaceuticals Inc received FDA approval for Aptiom, an antiepileptic medication. These milestones demonstrate the company's commitment to developing innovative therapies and improving the quality of life for patients with neurological disorders. Supernus Pharmaceuticals Inc continues to focus on research and development, aiming to achieve more breakthroughs in the pharmaceutical industry.

Supernus Pharmaceuticals Inc is primarily present in the United States and has a strong presence in North America. With its headquarters located in Rockville, Maryland, the company has successfully expanded its operations, research, and development efforts within the region. Supernus Pharmaceuticals Inc focuses on developing and commercializing innovative therapies for various central nervous system diseases. Its dedication to improving patient's quality of life and commitment to scientific advancement has allowed the company to establish itself as a key player in the pharmaceutical industry in the US and North America.

Supernus Pharmaceuticals Inc represents values of innovation, patient-centricity, and integrity. The company is dedicated to developing and commercializing innovative therapies that address unmet medical needs. With a strong focus on neurology and psychiatry, Supernus Pharmaceuticals Inc strives to improve the lives of patients by providing effective and safe treatment options. Their corporate philosophy revolves around conducting business ethically and responsibly while maintaining transparent and collaborative relationships with healthcare professionals, patients, and stakeholders. Through their commitment to research and development, Supernus Pharmaceuticals Inc aims to make a positive impact on the healthcare industry and enhance patient well-being.

Analyytikot asettavat tällä hetkellä Supernus Pharmaceuticals-osakkeelle keskimääräisen tavoitehinnan 65,00 USD (mediaani: 65,00 USD), mikä merkitsee +69,1 % viimeisimpään hintaan verrattuna. Konsensus perustuu 11 analyytikkoarvioon.

Supernus Pharmaceuticals Analyytikkojen kursstavoitteet 2026

11 analyytikkoa arvioi tällä hetkellä Supernus Pharmaceuticals-osaketta: 9 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Supernus Pharmaceuticals-yhtiöltä 879,07 M USD liikevaihtoa ja 2,56 USD osakekohtaista tulosta.

Supernus Pharmaceuticals Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Supernus Pharmaceuticals-osake noteerataan hintaan 34,18 EUR (38,43 USD).

Supernus Pharmaceuticals-osake (SUPN) on listattuna 7 pörssissä, muun muassa: NASDAQ (SUPN), London (0LB2.L), SIX (Zürich) (S49.SW), Frankfurt (S49.F), München (S49.MU), Düsseldorf (S49.DU).

Supernus Pharmaceuticals Inc is a leading biopharmaceutical company specializing in the development and marketing of innovative products for the treatment of central nervous system disorders. The company is headquartered in Rockville, Maryland, USA, and has offices in Canada and Europe. Supernus Pharmaceuticals Inc's business model is based on three core divisions: research and development, production, and distribution. The company aims to strengthen its research and development through strategic partnerships and acquisitions. Its product range includes a variety of drugs used to treat epilepsy, attention deficit/hyperactivity disorder (ADHD), and other drugs that affect the central nervous system. The main products of Supernus Pharmaceuticals Inc are the drugs Oxtellar XR and Trokendi XR, which are used to treat partial seizures in adults and children aged 6 and older. Oxtellar XR and Trokendi XR offer patients a once-daily dosage, increasing patient compliance and reducing the number of doses. Another important product of Supernus Pharmaceuticals Inc is Quillichew ER, used to treat ADHD in children. Quillichew ER is a once-daily chewable tablet, providing patients with a convenient way to take the medication. In addition to drug development and marketing, Supernus Pharmaceuticals Inc has also strengthened its production and distribution chain. The company owns a production facility in Montreal, Canada, and has an agreement with a company in Switzerland for drug manufacturing. The company has also entered into an agreement with a company to market Oxtellar XR, supporting sales efforts in Europe. Supernus Pharmaceuticals Inc directly distributes its products in the US and Canada. The company also has a distribution agreement with a company in Switzerland to distribute its products in Europe. In addition to drug development and marketing, Supernus Pharmaceuticals Inc operates a dedicated program to educate and support patients using its products. The company offers patient programs that provide support in medication compliance, disease management training, and access to special services and resources. Overall, Supernus Pharmaceuticals Inc has a strong business model based on the development and marketing of innovative drugs for the treatment of central nervous system disorders. The company aims to strengthen its research and development activities through strategic partnerships and acquisitions, and expand its presence internationally by strengthening its production and distribution chain. Supernus Pharmaceuticals Inc also remains committed to offering patient programs to support and care for patients using its products.

odotettu liikevaihto Supernus Pharmaceuticals on 879,07 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Supernus Pharmaceuticals on 147,08 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Supernus Pharmaceuticals:n hinta-voitto-suhde (P/E) on tällä hetkellä 14,98. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Supernus Pharmaceuticals-osakkeen arvostusta.

Supernus Pharmaceuticals:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,51. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Supernus Pharmaceuticals-osakkeen arvostuskennuslukuna.

Supernus Pharmaceuticals:n Eulpool-laatuscore on 2/10.

Supernus Pharmaceuticals:n ISIN on US8684591089. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Supernus Pharmaceuticals:n WKN on A1JX3U. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Supernus Pharmaceuticals:n ticker on SUPN. Tämä pörssinoteeraus käytetään Supernus Pharmaceuticals-osakkeiden kauppaan pörssissä.